ITGR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Integer Holdings Corp (ITGR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and recent insider confidence outweigh the technical neutrality and lack of immediate trading signals. The stock is positioned for growth in the coming years, making it a solid long-term investment.
The technical indicators are neutral. The MACD histogram is slightly negative at -0.183 but contracting, RSI is at 56.16 in the neutral zone, and moving averages are converging. The stock is trading below the pivot level of 89.583, with support at 82.979 and resistance at 96.188. No strong bullish or bearish signals are present.
Strong financial performance in 2025/Q4, with revenue up 5.02% YoY, net income up 48.63% YoY, and EPS up 53.33% YoY.
Positive analyst sentiment, with multiple upgrades and raised price targets (e.g., Raymond James to $101, Benchmark to $95).
Activist investor interest from Irenic Capital Management, which acquired a 13.7% stake, signaling confidence in the company's value.
Management projects stable adjusted EPS for 2026 between $6.29 and $6.78, indicating continued growth.
Concerns about underperforming products, which are expected to depress growth by 300-400 basis points in
High debt levels of $1.19 billion, which could limit financial flexibility.
Neutral trading sentiment from hedge funds and insiders, with no significant activity in the last quarter or month.
In 2025/Q4, Integer Holdings demonstrated strong financial growth: Revenue increased by 5.02% YoY to $472.06 million, net income rose by 48.63% YoY to $48.61 million, and EPS grew by 53.33% YoY to $1.38. Gross margin remained stable at 26.11%. The company also achieved an 8% sales growth in 2025 and a 21% increase in adjusted EPS, reflecting robust performance in the medical device sector.
Analysts are generally positive on ITGR. Raymond James raised the price target to $101 and maintains an Outperform rating, citing potential recovery by late 2026 and growth above the market in 2027. Benchmark upgraded the stock to Buy with a $95 price target after strong Q4 results and a $50M share repurchase program. Citi raised its target to $92 but maintains a Neutral rating, reflecting cautious optimism. Overall, analysts see long-term growth potential despite near-term headwinds.
